Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Dosing in Rheumatoid Arthritis
NCT05660655Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Disease Activity Score 28-C-reactive protein at 24 weeks. Started Oct 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05660655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660655.